All News

Founded in 1904, the National Association of Boards of Pharmacy is an impartial professional organization geared toward supporting the efforts of individual state boards of pharmacy to protect the public health and safety.

New Products

A survey of new Rx, new generic, and new OTC products

Come together

A shortage of primary care physicians, decreased reimbursement, and increased complexity of patient care can make delivering patient care harder than ever. A new Asheville model shows what teamwork can accomplish.

As expected, the U.S. Supreme Court recently struck down a landmark case that would have prohibited data-mining companies from selling physicians' prescribing information to pharmaceutical manufacturers for use in marketing. Still some independent pharmacists say they are not in favor of the practice.

Letters July 2011

Readers speak out about the moratorium on new pharmacy schools, pharmacist turnover and the POWER program, job satisfaction, and more

A pharmacy student who works in a retail pharmacy and has completed several clinical and community rotations has not seen wide implementation of MTM at any level.

According to new guidelines, researchers at the Alzheimer's Association and the National Institute of Aging of the National Institutes of Health have categorized AD into 3 different stages: preclinical, mild cognitive impairment, and Alzheimer's dementia.

While academe is working toward training people to work in an environment of interdisciplinary teamwork, what is needed is a shift in our sense of community in the workplace, a broadening of our sense of who we are and what our place is in the larger patient-care environment.

If you dare to deny the importance of your technicians, try leaving them out of the mix for just 1 week; you'll see your business come to a grinding halt.

Chronic cluster headaches are debilitating for patients who experience them. A recent study concluded that low-intensity anticoagulation with warfarin was associated with significantly higher incidence of remission and less headache impact on patients' lives.

FDA has issued a new draft guidance to facilitate the development and review of companion diagnostics ? tests used to help healthcare professionals determine whether a patient with a particular disease or condition should receive a particular drug therapy or how much of the drug to give. The draft document is intended to provide companies with guidance on the agency's policy for reviewing a companion diagnostic and the corresponding therapy.

While the National Community Pharmacists Association (NCPA) is in favor of the Medicaid Access Rule proposed by the Centers for Medicare and Medicaid Services (CMS), it has several concerns about the proposal.

Duane Reade?s new flagship store on Wall Street in New York City features sushi chefs and a new connection to Walgreens? pharmacy network. The Duane Reade store signals a prototype for future Duane Reade stores. Duane Reade is owned by Walgreens and has more than 250 stores in the New York City region.

Low-cost generic drug programs pioneered by Wal-Mart and other big-box retailers are a mixed blessing for patients with diabetes. The loss-leader strategy used by big-box, chain, independent, and online pharmacies has boosted the mean cost of branded diabetes medications by up to 113% since 2008.

David D. Pope, PharmD, CDE, editor-in-chief of CreativePharmacist.com, has developed and directs an innovative, web-based program titled HealthyHeartClub.com, which offers accountability, encouragement, and education to help patients adopt healthier lifestyles and decrease cardiovascular risk.

FDA has approved Boostrix [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap); GlaxoSmithKline Biologicals] for use in adults aged 65 years and older for active booster immunization against tetanus, diphtheria, and pertussis (whooping cough). This approval makes Boostrix the first Tdap vaccine approved for use by this age group.

Dronedarone (Multaq, Sanofi), which is approved for nonpermanent atrial fibrillation (AF), was being tested on patients with permanent AF. However, that trial, PALLAS (Permanent Atrial fibrillation outcome Study using Dronedarone on top of standard therapy) phase 3b, has been terminated because it was causing increased cardiovascular events.